The Oral controlled - release formulations for the small intestine and colon have received considerable attention in the past 25 years for a variety of reasons including pharmaceutical superiority and clinical benefits derived from the drug - release pattern that are not achieved with traditional immediate (or) sustained - release products Although 5-FU is a widely used antineoplastic agent, the cytotoxicity is not limited to tumor cells. Hematopoietic cells and normal epithelial cells of GI tract are susceptible to 5-FU induced cytotoxicity, which produces sever leucopenia and intestinal toxicity leading to lethal translocation of intestinal microflora. The clinical use of 5-FU is limited by its GI toxicity (stomatitis) and myelotoxicity1, and oral bioavailability was found to be only 28% in humans. On other hand, severe systemic toxic effects and shorter half life make this drug particularly suitable to be delivered by local delivery system providing continuously sustained release1. Targeted delivery of 5- FU not only reduces systemic side effects, but also would provide an effective and safe therapy for colon cancer with reduced dose and duration of therapy.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : October 14, 2019